Sugammadex Safely Reverses Muscle Paralysis in Babies Under 2 Years Old
First randomized trial shows sugammadex outperforms neostigmine for reversing surgical paralysis in neonates and infants, with a strong safety profile.
Summary
A phase IV multicenter randomized trial tested sugammadex — a drug that reverses surgical muscle paralysis — in 138 children aged 1 to 720 days. The 2 mg/kg dose reversed moderate neuromuscular blockade nearly three times faster than the standard drug neostigmine (1.4 vs. 4.4 minutes). The 4 mg/kg dose rapidly reversed deep blockade in about 1.1 minutes. Pharmacokinetic data showed no dose adjustments were needed for younger age groups. No drug-related serious adverse events, deaths, or allergic reactions occurred. This trial provides the first robust clinical evidence supporting sugammadex use in the youngest pediatric patients, filling a critical gap in neonatal and infant anesthesia care.
Detailed Summary
Reversing surgical muscle paralysis safely and quickly in neonates and infants is a high-stakes clinical challenge. Until now, sugammadex — which works by encapsulating the paralytic drugs rocuronium or vecuronium — had only been formally validated in adults and children 2 years and older. This phase IV trial is the first randomized controlled study to rigorously test sugammadex in children under 2 years of age, including newborns as young as 1 day old.
The trial enrolled 138 participants (ages 1–720 days) across 23 centers in 12 countries between 2019 and 2023. It was structured in two parts. Part A was open-label and used pharmacokinetic blood sampling to determine whether age-specific dose adjustments were needed. Participants were enrolled in four sequential age cohorts — from oldest (6 months to <2 years) down to youngest (birth to 27 days) — with safety data reviewed by an independent committee between cohorts. Part B was double-blind and randomized participants 1:1:1 to: moderate blockade reversed with 2 mg/kg sugammadex; moderate blockade reversed with neostigmine plus glycopyrrolate or atropine; or deep blockade reversed with 4 mg/kg sugammadex.
Pharmacokineticfindings from Part A confirmed that sugammadex clearance, volume of distribution, and half-life were comparable across all four pediatric age cohorts and consistent with adult data, justifying the same weight-based dosing without age-based adjustments. The primary efficacy endpoint — time to neuromuscular recovery (TTNMR), defined as recovery to a train-of-four ratio ≥0.9 — showed that 2 mg/kg sugammadex achieved a median TTNMR of 1.4 minutes compared to 4.4 minutes for neostigmine (hazard ratio 2.40; 95% CI 1.37–4.18; P=0.0002). The 4 mg/kg dose reversed deep blockade in a median of 1.1 minutes across both study parts.
The safety profile was reassuring. The proportion of participants experiencing one or more adverse events was similar between sugammadex and neostigmine groups. There were no deaths, no drug-related serious adverse events, and no confirmed hypersensitivity or anaphylaxis events. Clinically relevant bradycardia events were monitored carefully given the known cholinergic effects of neostigmine, but no signal distinguishing the groups was reported as a major finding.
This trial fills an important evidence gap in pediatric anesthesia. Neonates and infants are at higher risk from residual neuromuscular blockade due to immature respiratory musculature and neuromuscular junction development. Having a fast, predictable, and well-tolerated reversal agent validated for this age group could meaningfully reduce postoperative respiratory complications. The results support extending current adult and older-pediatric dosing guidelines for sugammadex to children under 2 years without modification.
Key Findings
- 2 mg/kg sugammadex reversed moderate blockade in 1.4 min vs. 4.4 min for neostigmine (HR 2.40, P=0.0002).
- 4 mg/kg sugammadex reversed deep neuromuscular blockade in a median of 1.1 minutes.
- Pharmacokinetics were consistent across all four age cohorts; no dose adjustments needed for age.
- No deaths, drug-related serious adverse events, or anaphylaxis events were reported in 138 participants.
- Adverse event rates were similar between sugammadex and neostigmine groups across all ages.
Methodology
Phase IV randomized multicenter trial (23 centers, 12 countries, 2019–2023) enrolling 138 participants aged 1–720 days in two parts: open-label pharmacokinetic evaluation (Part A) and double-blind active-comparator-controlled efficacy/safety assessment (Part B). Randomization was stratified by age cohort and neuromuscular blocking agent; primary endpoint was time to train-of-four ratio ≥0.9.
Study Limitations
The trial was industry-sponsored by Merck (manufacturer of sugammadex), which introduces potential conflict-of-interest considerations. Sample sizes per age cohort were relatively small, particularly for neonates under 28 days, limiting statistical power for subgroup analyses. Preterm infants under 36 weeks gestational age were excluded, leaving that subset without evidence.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.